Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Force of Positive Reasoning: Day to day Attestations - 2Protester climbs on to balcony of Iranian embassy in London
- 3Nepal’s youngest premier sworn in after releasing new rap song about unity
- 4Discovering a sense of harmony: Individual Accounts of Reflection and Care
- 5Step by step instructions to Analyze Senior Insurance Contracts Really.
- When does Spotify Wrapped come out? The music streamer says 'soon.'
- Is an $85 apple pie worth it? Our Thanksgiving taste test says … maybe.
- UN panel says Israel operating 'de facto policy of torture'
- Avoid Slam: Exploring the Pickup Truck Transformation
- 7 Extraordinary Efficiency Applications for Experts
- Fuel Price Spike Drives Surge in Used EV Sales in Europe
- Russia earning billions from Hormuz blockade, German trade body says
- Well known SUVs With Low Energy Utilization In 2024
- Congolese rape survivors search in vain for medicine after USAID cuts
